WASHINGTON, March 10 (Reuters) - Eli Lilly & Co.'s (LLY.N: Quote, Profile, Research) cancer drug Gemzar, used in combination with a chemotherapy agent, “has no apparent effect on survival at a cost of increased toxicity” for patients with advanced ovarian cancer, U.S. regulatory staff said on Friday.
